KR20220130151A - 비장비대의 치료 방법 - Google Patents

비장비대의 치료 방법 Download PDF

Info

Publication number
KR20220130151A
KR20220130151A KR1020227027305A KR20227027305A KR20220130151A KR 20220130151 A KR20220130151 A KR 20220130151A KR 1020227027305 A KR1020227027305 A KR 1020227027305A KR 20227027305 A KR20227027305 A KR 20227027305A KR 20220130151 A KR20220130151 A KR 20220130151A
Authority
KR
South Korea
Prior art keywords
weeks
myelofibrosis
bid
human subject
btk inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227027305A
Other languages
English (en)
Korean (ko)
Inventor
웨인 필립 로스바움
Original Assignee
텔리오스 파마, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 텔리오스 파마, 인크. filed Critical 텔리오스 파마, 인크.
Publication of KR20220130151A publication Critical patent/KR20220130151A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Processing Of Solid Wastes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
KR1020227027305A 2020-01-08 2021-01-08 비장비대의 치료 방법 Pending KR20220130151A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062958632P 2020-01-08 2020-01-08
US62/958,632 2020-01-08
PCT/US2021/012696 WO2021142257A1 (en) 2020-01-08 2021-01-08 Methods of treating splenomegaly

Publications (1)

Publication Number Publication Date
KR20220130151A true KR20220130151A (ko) 2022-09-26

Family

ID=76788747

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227027305A Pending KR20220130151A (ko) 2020-01-08 2021-01-08 비장비대의 치료 방법

Country Status (15)

Country Link
EP (2) EP3980069A4 (https=)
JP (2) JP7771064B2 (https=)
KR (1) KR20220130151A (https=)
CN (1) CN114423457A (https=)
AU (1) AU2021205484A1 (https=)
BR (1) BR112022013646A2 (https=)
CA (1) CA3164063A1 (https=)
CO (1) CO2022010592A2 (https=)
CR (1) CR20220374A (https=)
IL (1) IL294582A (https=)
JO (1) JOP20220168A1 (https=)
MA (3) MA63848B1 (https=)
MX (1) MX2022008490A (https=)
TN (1) TN2022000185A1 (https=)
WO (1) WO2021142257A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3980069A4 (en) * 2020-01-08 2022-08-17 Telios Pharma, Inc. METHODS OF TREATMENT OF SPLENOMEGALY
US20240024314A1 (en) 2020-01-08 2024-01-25 Telios Pharma, Inc. Methods of Treating Splenomegaly
IL309238A (en) * 2021-06-16 2024-02-01 Telios Pharma Inc Treatment of symptoms associated with myeloproliferative tumors
WO2023071973A1 (en) * 2021-10-26 2023-05-04 Shenzhen Targetrx, Inc. Fused bicyclic compound for inhibiting activity of tyrosine kinase
CN119677518A (zh) * 2022-08-25 2025-03-21 百济神州(苏州)生物科技有限公司 包含(s)-7-(1-丙烯酰基哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氢吡唑并[1,5-a]嘧啶-3-甲酰胺和草酸的固体形式、其组合物及其使用方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015057992A1 (en) * 2013-10-16 2015-04-23 Izumi Raquel Btk inhibitors for hematopoietic mobilization
WO2015081127A2 (en) 2013-11-26 2015-06-04 Gilead Sciences, Inc. Therapies for treating myeloproliferative disorders
MA40596B1 (fr) * 2014-08-11 2021-12-31 Acerta Pharma Bv Combinaisons thérapeutiques d'un inhibiteur de btk et d'un inhibiteur de bcl-2
WO2016054491A1 (en) * 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN112313214A (zh) * 2018-06-19 2021-02-02 默克专利有限公司 1-(4-{[6-氨基-5-(4-苯氧基-苯基)-嘧啶-4-基氨基]-甲基}-4-氟代-哌啶-1-基)-丙烯酮及其盐形式的新晶体形式以及获得方法
CN109942835A (zh) * 2019-03-27 2019-06-28 广州楹鼎生物科技有限公司 一种催化分解木质纤维原料的方法
TW202128156A (zh) * 2019-11-14 2021-08-01 美商夸格智財控股有限公司 用於癌症治療之btk抑制劑及mdm2抑制劑之組合
EP3980069A4 (en) * 2020-01-08 2022-08-17 Telios Pharma, Inc. METHODS OF TREATMENT OF SPLENOMEGALY

Also Published As

Publication number Publication date
EP4000624A1 (en) 2022-05-25
AU2021205484A1 (en) 2022-08-18
JP2026027353A (ja) 2026-02-18
MA57226B1 (fr) 2023-06-28
CR20220374A (es) 2023-01-25
MA57226A1 (fr) 2023-02-28
EP3980069A1 (en) 2022-04-13
JOP20220168A1 (ar) 2023-01-30
CO2022010592A2 (es) 2022-10-31
MX2022008490A (es) 2022-10-13
MA63848A1 (fr) 2024-04-30
JP2023509968A (ja) 2023-03-10
MA63848B1 (fr) 2024-10-31
TN2022000185A1 (en) 2024-04-01
MA69153A1 (fr) 2025-07-31
CA3164063A1 (en) 2021-07-15
WO2021142257A1 (en) 2021-07-15
JP7771064B2 (ja) 2025-11-17
BR112022013646A2 (pt) 2022-10-04
IL294582A (en) 2022-09-01
EP3980069A4 (en) 2022-08-17
CN114423457A (zh) 2022-04-29

Similar Documents

Publication Publication Date Title
KR20220130151A (ko) 비장비대의 치료 방법
KR20230151057A (ko) 혈소판 유래 성장 인자 수용체 알파의 유전적 이상과 연관된 암 치료를 위한 1-[4-브로모-5-[1-에틸-7-(메틸아미노)-2-옥소-1,2-다이히드로-1,6-나프티리딘-3-일]-2-플루오로페닐]-3-페닐우레아 및 유사체의 용도
TW201840337A (zh) 使用ｈｓｐ９０抑制劑治療癌症的方法
AU2019263064B2 (en) Methods of treating cancer
WO2021127496A1 (en) Combination treatments for waldenstrom's macroglobulinemia
CN114901265A (zh) 用于癌症治疗的btk抑制剂和mdm2抑制剂的组合
TW201922256A (zh) 治療淋巴樣惡性疾病之方法
WO2014081712A2 (en) Methods of treating a disease or disorder associated with bruton's tyrosine kinase
WO2022266285A1 (en) Treatment of symptoms associated with myeloproliferative neoplasms
US11642343B2 (en) Methods of treating splenomegaly
AU2023390908A1 (en) Methods of treating myeloproliferative neoplasms
HK40078282A (en) Btk inhibitors for treating splenomegaly
WO2026024885A1 (en) Rilzabrutinib for treating warm antibody autoimmune hemolytic anemia
EA045240B1 (ru) Способы лечения рака
HK40069821A (en) Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignancies
Parmar et al. Cancer Chemotherapy: Recent Developments in Hematology Oncology

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000